Literature DB >> 19889145

Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats.

Annamaria Morelli1, Sandra Filippi, Paolo Comeglio, Erica Sarchielli, Aravinda K Chavalmane, Linda Vignozzi, Benedetta Fibbi, Enrico Silvestrini, Peter Sandner, Mauro Gacci, Marco Carini, Gabriella B Vannelli, Mario Maggi.   

Abstract

INTRODUCTION: In human bladder, phosphodiesterase type 5 (PDE5) is present not only in the muscular wall but also in the vascular beds, suggesting a role for PDE5 inhibitors in favoring bladder blood flow and tissue oxygenation. AIM: To investigate whether acute administration of vardenafil could affect bladder oxygenation in spontaneously hypertensive rats (SHR), an animal model of naturally occurring overactive bladder. MAIN OUTCOME MEASURES: The effect of vardenafil on hypoxia-induced alterations was studied in vivo in SHR by acute dosing (10 mg/kg, 90 minutes before sacrifice) and in vitro in human bladder smooth muscle cells (hBCs).
METHODS: Bladder oxygenation was detected using the hypoxyprobe immunostaining. The expression of some hypoxia markers (vascular endothelial growth factor [VEGF] and endothelin-1 type B [ETB] receptor) was also evaluated by immunohistochemistry and Western blot. Gene expression in hBC was quantified by real-time reverse transcription-polymerase chain reaction.
RESULTS: Rat bladder PDE5 immunopositivity was detected in the muscular wall and in the endothelial and smooth muscle cells of blood vessels. In SHR bladder, a significant increase of hypoxic cells, VEGF, and ETB expression was observed when compared with their normotensive counterpart Wistar Kyoto rats (WKY). Vardenafil treatment dramatically decreased hypoxyprobe staining, as well as VEGF and ETB expression in SHR bladder up to WKY level. Accordingly, in SHR bladder, vardenafil administration significantly blunted relaxation induced by the selective ETB agonist IRL-1620. In hBCs, experimental hypoxia significantly induced gene expression of hypoxia markers (carbonic anhydrase IX and VEGF), which was not changed by simultaneous treatment with vardenafil. Conversely, the hypoxia-related induction of smooth muscle-specific genes (alphaSMA, SM22alpha, and desmin) was significantly reduced by vardenafil.
CONCLUSIONS: SHR showed bladder hypoxia which was significantly reduced by acute vardenafil treatment. Thus, besides relaxing muscular wall, PDE5 inhibition may positively affect urinary vesicle blood perfusion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889145     DOI: 10.1111/j.1743-6109.2009.01558.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  20 in total

1.  Do AB0 blood groups affect lower urinary tract symptoms?

Authors:  Erdal Benli; Abdullah Çırakoğlu; Ercan Öğreden; Yasemin Kaya; Ali Ayyıldız; Ahmet Yüce
Journal:  Turk J Urol       Date:  2018-11-19

Review 2.  Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.

Authors:  M Gacci; M Carini; M Salvi; A Sebastianelli; L Vignozzi; G Corona; M Maggi; K T McVary; S A Kaplan; M Oelke; S Serni
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

Review 3.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

Review 4.  [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].

Authors:  A Herlemann; C Gratzke; K-E Andersson; K D Sievert
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

Review 5.  Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.

Authors:  Osamu Yokoyama; Yasuhiko Igawa; Masayuki Takeda; Takafumi Yamaguchi; Masahiro Murakami; Lars Viktrup
Journal:  Ther Adv Urol       Date:  2015-10

6.  The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis.

Authors:  Su-Jin Shin; Kwang-Ho Lee; Kyung-Sook Chung; Se-Yun Cheon; Hyo-Jin An
Journal:  Exp Ther Med       Date:  2017-01-25       Impact factor: 2.447

7.  Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer.

Authors:  M Gacci; G Corona; G Apolone; A Apolone; M Lanciotti; N Tosi; S Giancane; L Masieri; S Serni; M Maggi; M Carini
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-03-09       Impact factor: 5.554

Review 8.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 9.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12

10.  Functional nitrergic innervation of smooth muscle structures in the mucosa of pig lower urinary tract.

Authors:  Retsu Mitsui; Yota Chikada; Keiji Arai; Hikaru Hashitani
Journal:  Cell Tissue Res       Date:  2021-10-04       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.